National clinical guidelines for childhood wheeze exist, yet despite being one of the commonest reasons for childhood Emergency Department (ED) attendance, significant variation in practice occurs in other settings. We therefore evaluated practice variations of ED clinicians in the UK and Ireland. 
INTRODUCTION
Asthma is the commonest chronic medical condition of childhood, with rates in the UK and Ireland amongst the highest in the world. [1] [2] [3] [4] It remains a significant cause of mortality and morbidity and the NHS spends £1 billion on asthma annually, with costs higher in children than adults. 4 In the context of increasing childhood admission rates asthma accounts for 64-73% of those for chronic conditions, and wheezing is one of the commonest reasons for hospitalisation overall. 5, 6 Whilst there is variation in severity and pathophysiology with overlap between asthma and viral induced wheeze (VIW), wheezing is consistently identified as a leading presentation to Emergency Departments (EDs) in other healthcare settings. [7] [8] National guidelines and quality standards exist for the management of wheezing. [9] [10] [11] Many recommendations derive from high quality studies, but some are based on lesser evidence or expert consensus. Paucity of evidence results in guidance which cannot provide detail in some areas, potentially leading to individual interpretation and practice variation as in other systems. 12, 13 This may contribute to differences in admission rates, bed days and length of stay across English primary care trusts. 5 Practice variation may result in poorer health outcomes, unnecessary medical treatments, and increased strain on the healthcare system. 14 Determining baseline practice and identifying variation in wheeze management will highlight areas where implementing existing guidance could improve care, and identify key areas for future research.
We aimed to determine whether variation exists in the clinical care of acute severe childhood wheeze across the UK and Ireland through a survey completed by senior clinical decision makers.
The survey examined differences in approach to severe wheeze, and the use of inhaled, oral, and intravenous (IV) therapies. 
METHODS
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RESULTS
Thirty
Intravenous bronchodilators
170 (92.9%) use IV salbutamol, though in a range of strategies and doses. For the purposes of this study a continuous infusion was defined as a "weight based rate (micrograms/kg/min) with no fixed endpoint"; a loading dose as a "weight based rate (micrograms/kg/min) given for a set period of time"; and a bolus as a "weight based dose (micrograms/kg)". Five general strategies are employed, the most common being "bolus and continuous infusion". For boluses, four doses and seven durations were described. There were ten different continuous infusion rates with over tenfold variation between the lowest and highest. (Table 4) 142 (77.6%) use aminophylline, with 127 (89.4%) giving "bolus and infusion". 132 (93%) give a bolus, of which 120 (91%) give 5mg/kg. 5 (3.8%) give each of 6mg/kg or 7.5mg/kg and one 10mg/kg. 120 (91%) give the bolus over 20-30 minutes. Nine continuous infusion rates were described, all at 1mg/kg/hr or less, with 1mg/kg/hr being the most common (68.6%). total histamine blockade (1, 0.5%), intravenous ketamine (1, 0.5%), or monteleukast (1, 0.5%).
DISCUSSION
In establishing baseline practice across a range of sites and clinicians in the UK and Ireland, we have demonstrated variation in management of acute severe childhood wheeze. This exists in assessment and treatment, especially inhaled and IV bronchodilator selection, dosage and frequency, reflecting the paucity of evidence underpinning recommendations.
CPGs such as BTS/SIGN national guidance 9 assist clinicians in healthcare decisions and are underpinned by best available evidence. CPs translate and clarify CPGs, including timing and dosage of treatment, and as a result they streamline management plans across handovers, reduce variability and errors in care, prompt use of best evidence, improve education, and potentially shorten length of stay.
14,16
The CPGs we collected were based on BTS/SIGN guidance 9 varying mainly in bronchodilator selection/dosage and system processes. 40% had a wheeze CP, representing an opportunity to share best practice. In future CPs should capitalise on available technology and be used across all healthcare settings, including primary care, EDs, and inpatient settings.
Variations in inhaled therapy included delivery method, drug selection, dosage and frequency. Most used MDIs in children with no oxygen requirement, though one-fifth always used nebulisers. Most gave the BTS/SIGN salbutamol MDI dose, though some tended towards lower doses in younger children. Ipratropium bromide use is more varied as in other healthcare systems, perhaps due to conflicting literature. 13 However in a recent systematic review children treated with ipratropium bromide and salbutamol compared to salbutamol alone have lower rates of hospital admission, nausea and tremor, and greater improvement in lung function. 17 More than half used salbutamol as the first-line IV agent while fewer preferred magnesium sulphate or aminophylline, suggesting equipoise regarding which is most efficacious. To investigate this we asked participants whether they would enrol patients to a randomised controlled trial allocating salbutamol, aminophylline or magnesium sulphate as the first line IV agent, to which 148 (80.9%) responded positively.
Uncertainty exists regarding the optimal dose and administration strategy, especially for salbutamol, contributed to by numerous dosage terminologies. We defined these terms through reference to available CPGs, though some would reserve the term "loading" for a dose which is followed by continuous infusion and "bolus" for a dose not followed by an infusion. There is threefold and tenfold variation in bolus doses and continuous infusion rates respectively, and infrequent usage of loading doses, reflecting the paucity of evidence on the pharmacokinetics of IV salbutamol.
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BTS/SIGN guidelines suggest a bolus of 15micrograms/kg over 10 minutes, followed by an infusion of 1-5micrograms/kg/minute if required with no loading dose described. Key studie s suggest a bolus of 15micrograms/kg 19 or a loading dose of 5micrograms/kg/minute for one hour. 20, 21 Respectively these are equivalent to 1.5micrograms/kg/minute 19 (the lower end of guidance), or a total dose of 300micrograms/kg 20, 21 (20 times that suggested by guidance). In further analysing the dose given prior to any continuous infusion, there is 60-fold variation between a single 5micrograms/kg dose, and a dose of 5micrograms/kg/minute given for one hour.
Knowledge translation may take several years, 14 though, recent evidence may result in practice change. For example, a recent trial of inhaled magnesium sulphate reported improvement in a subset of children, 22, 23 and oral dexamethasone may provide an alternative to prednisolone, appearing at least as effective and more palatable. [24] [25] [26] [27] [28] [29] Variation may be reduced by dissemination of research and sharing of best practice across networks.
There is therefore a need for rigorously conducted multicentre research on topics including development of a minimum data set, identification of wheeze phenotypes, and the optimal strategies for treatment of acute severe wheeze. These include studies on inhaled bronchodilators in the first hour, IV bronchodilator selection, dexamethasone compared to prednisolone, and other therapies such as inhaled steroids. Several of these were identified as important to clinicians through a research prioritisation exercise performed by PERUKI. 30 Only in answering these questions can variation be reduced and clinical care improved in this important, common, and potentially lifethreatening condition.
LIMITATIONS
This study relied on accurate reporting by individual clinicians. However our approach allowed us to analyse practice of a large number of consultant clinicians from a number of regions, and our high response rate means we are confident we have identified key variations. We did not focus on a wider range of practitioners, but this is reasonable given many EDs have a consultant-delivered service. We have identified variation in practice, but cannot determine best practice. However our methods allow assessment of variation, outline areas for implementation, and highlight areas in which there is a paucity of evidence. We assessed a range of practice points in a short time and identified areas for investigation, the first of which has been completed 31
CONCLUSIONS
Variation exists in the assessment and treatment of acute severe childhood wheeze across the UK and Ireland. Key areas include inhaled and IV bronchodilator selection, dosage and frequency, reflecting the paucity of evidence. We have identified opportunities for best practice dissemination and highlighted clinical questions which must be answered by robust multicentre research to improve clinical care of this common childhood condition.
WHAT IS KNOWN ON THIS TOPIC
Childhood asthma is the most common chronic medical condition of childhood, and one of the most common reasons for attendance to urgent and emergency care and admission to hospital.
National guidance exists for the management of acute childhood wheeze, though there is a paucity of evidence in some areas of practice.
Variation in treatment and investigation of acute childhood wheeze has been demonstrated in other settings, and variation in hospitalisation rates across primary care trusts exists in our setting.
WHAT THIS STUDY ADDS
Across the UK & Ireland variation exists in the treatment of acute severe childhood wheeze, especially in inhaled and intravenous bronchodilator selection, dosage and frequency.
We have identified key areas of variation, which require further exploration to determine their impact at the patient interface.
There is an urgent need for multicentre studies to address the paucity of evidence for management of severe childhood wheeze to inform recommendations.
